相似文献
1
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Br J Cancer. 2005 Jul 25;93(2):173-7. doi: 10.1038/sj.bjc.6602698.
2
Docetaxel (Taxotere) in the treatment of cancer.
Semin Oncol. 2000 Apr;27(2 Suppl 3):1-2.
3
Docetaxel in the treatment of advanced non-small-cell lung cancer.
Expert Rev Anticancer Ther. 2008 Aug;8(8):1207-22. doi: 10.1586/14737140.8.8.1207.
4
Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Eur J Cancer. 2005 May;41(8):1117-26. doi: 10.1016/j.ejca.2005.02.016.
5
Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors.
Drugs Today (Barc). 2006 Apr;42(4):265-79. doi: 10.1358/dot.2006.42.4.968648.
6
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Cancer Treat Rev. 2006 Dec;32(8):583-7. doi: 10.1016/j.ctrv.2006.07.003. Epub 2006 Aug 21.
7
Docetaxel in advanced non-small cell lung cancer.
Expert Rev Anticancer Ther. 2005 Feb;5(1):13-24. doi: 10.1586/14737140.5.1.13.
8
Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.
Cancer Chemother Pharmacol. 2004 Sep;54(3):230-6. doi: 10.1007/s00280-004-0826-x. Epub 2004 May 4.
9
[Toward the cure of "early-stage" solid tumors: the role of docetaxel].
Tumori. 2005 Jul-Aug;91(4):suppl 17-28.
10
Docetaxel: a review of its pharmacology and clinical activity.
Can J Oncol. 1996 Jun;6(1):443-57.
引用本文的文献
1
Oral Metronomic Delivery of Atorvastatin and Docetaxel via Transporter-Targeted Nanoemulsions Enhances Antitumor Efficacy and Immune Modulation in Colon Cancer.
Pharmaceutics. 2025 Jul 2;17(7):872. doi: 10.3390/pharmaceutics17070872.
2
PEGylated Liposomes of Disulfiram and Paclitaxel: A Promising Chemotherapeutic Combination Against Chemoresistant Breast Cancer.
Pharmaceuticals (Basel). 2025 Mar 28;18(4):487. doi: 10.3390/ph18040487.
3
Behavioral Responses to Healthcare Funding Decisions and Their Impact on Value for Money: Evidence From Australia.
Health Econ. 2025 Jul;34(7):1239-1254. doi: 10.1002/hec.4958. Epub 2025 Mar 18.
4
DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment.
Investig Clin Urol. 2025 Jan;66(1):56-66. doi: 10.4111/icu.20240263.
5
Characterization and Evaluation of Nano-niosomes Encapsulating Docetaxel against Human Breast, Pancreatic, and Pulmonary Adenocarcinoma Cancer Cell Lines.
J Biomed Phys Eng. 2024 Apr 1;14(2):159-168. doi: 10.31661/jbpe.v0i0.2401-1708. eCollection 2024 Apr.
6
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.
Genes Dis. 2022 Mar 18;10(4):1367-1401. doi: 10.1016/j.gendis.2022.02.007. eCollection 2023 Jul.
7
A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2.
Viruses. 2022 Sep 29;14(10):2150. doi: 10.3390/v14102150.
8
Evaluation of a 4-day repeated-dose micronucleus test in rat glandular stomach and colon using aneugens and non-genotoxic non-carcinogens.
Genes Environ. 2022 Apr 11;44(1):12. doi: 10.1186/s41021-022-00241-6.
9
State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent.
Cancers (Basel). 2022 Feb 21;14(4):1089. doi: 10.3390/cancers14041089.
10
Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
Breast Cancer Res Treat. 2022 Feb;192(1):75-87. doi: 10.1007/s10549-021-06490-3. Epub 2022 Jan 26.
本文引用的文献
1
Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Eur J Cancer. 2005 May;41(8):1117-26. doi: 10.1016/j.ejca.2005.02.016.
2
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
J Clin Oncol. 2005 Feb 20;23(6):1070-7. doi: 10.1200/JCO.2005.03.082.
3
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
J Clin Oncol. 2005 Feb 20;23(6):1061-9. doi: 10.1200/JCO.2005.11.036. Epub 2005 Jan 18.
4
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Clin Pharmacol Ther. 2005 Jan;77(1):43-53. doi: 10.1016/j.clpt.2004.09.005.
5
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Clin Cancer Res. 2004 Nov 1;10(21):7220-8. doi: 10.1158/1078-0432.CCR-04-0452.
6
Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Cancer Chemother Pharmacol. 2005 Jan;55(1):72-8. doi: 10.1007/s00280-004-0864-4. Epub 2004 Aug 17.
7
Dexamethasone as a probe for docetaxel clearance.
Cancer Chemother Pharmacol. 2004 Sep;54(3):265-72. doi: 10.1007/s00280-004-0823-0. Epub 2004 May 5.
8
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clin Pharmacol Ther. 2004 May;75(5):448-54. doi: 10.1016/j.clpt.2004.01.001.
9
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
Eur J Cancer. 2004 May;40(8):1269-74. doi: 10.1016/j.ejca.2004.01.024.
10
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
Eur J Cancer. 2004 May;40(8):1170-8. doi: 10.1016/j.ejca.2003.12.026.
Zotero 插件